[go: up one dir, main page]

GB202311382D0 - Lyophilised compostion - Google Patents

Lyophilised compostion

Info

Publication number
GB202311382D0
GB202311382D0 GBGB2311382.2A GB202311382A GB202311382D0 GB 202311382 D0 GB202311382 D0 GB 202311382D0 GB 202311382 A GB202311382 A GB 202311382A GB 202311382 D0 GB202311382 D0 GB 202311382D0
Authority
GB
United Kingdom
Prior art keywords
compostion
lyophilised
lyophilised compostion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2311382.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority to GBGB2311382.2A priority Critical patent/GB202311382D0/en
Publication of GB202311382D0 publication Critical patent/GB202311382D0/en
Priority to PCT/IB2024/057178 priority patent/WO2025022327A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB2311382.2A 2023-07-25 2023-07-25 Lyophilised compostion Ceased GB202311382D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2311382.2A GB202311382D0 (en) 2023-07-25 2023-07-25 Lyophilised compostion
PCT/IB2024/057178 WO2025022327A1 (en) 2023-07-25 2024-07-24 Lyophilised composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2311382.2A GB202311382D0 (en) 2023-07-25 2023-07-25 Lyophilised compostion

Publications (1)

Publication Number Publication Date
GB202311382D0 true GB202311382D0 (en) 2023-09-06

Family

ID=87852076

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2311382.2A Ceased GB202311382D0 (en) 2023-07-25 2023-07-25 Lyophilised compostion

Country Status (2)

Country Link
GB (1) GB202311382D0 (en)
WO (1) WO2025022327A1 (en)

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0702690A1 (en) * 1994-04-07 1996-03-27 Akzo Nobel N.V. Freeze-dried compositions comprising rna
CA2414884A1 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
EP2189473A3 (en) 2000-10-27 2010-08-11 Novartis Vaccines and Diagnostics S.r.l. Nucleic and proteins from streptococcus groups A & B
WO2003018054A1 (en) 2001-08-31 2003-03-06 Chiron Srl. Helicobacter pylori vaccination
CN1812809A (en) 2003-06-26 2006-08-02 希龙公司 Immunogenic compositions for chlamydia trachomatis
EP1648500B1 (en) 2003-07-31 2014-07-09 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for streptococcus pyogenes
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
DK1751289T3 (en) 2004-05-18 2009-05-11 Alphavax Inc TC-83-derived alphavirus vectors, particles and methods
WO2006089264A2 (en) 2005-02-18 2006-08-24 Novartis Vaccines And Diagnostics Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
NZ580974A (en) 2005-02-18 2011-05-27 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
CA2602665A1 (en) 2005-03-30 2006-10-19 Novartis Vaccines And Diagnostics, Inc. Haemophilus influenzae type b
US8133973B2 (en) 2005-05-12 2012-03-13 Novartis Vaccines And Diagnostics, S.R.L. Immunogenic compositions for Chlamydia trachomatis
AU2006307602A1 (en) 2005-10-25 2007-05-03 Novartis Vaccines And Diagnostics Srl Compositions comprising Yersinia pestis antigens
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0717187D0 (en) 2007-09-04 2007-10-17 Novartis Ag Compositions comprising yersinia pestis antigens
ITMI20081249A1 (en) 2008-07-09 2010-01-09 Novartis Vaccines & Diagnostic ESCHERICHIA COLI IMMUNOGENES WITH IMPROVED SOLUBILITY.
WO2009109860A2 (en) 2008-03-06 2009-09-11 Novartis Ag Mutant forms of chlamydia htra
KR20120034612A (en) 2009-04-14 2012-04-12 노파르티스 아게 Compositions for immunising against staphylococcus aureus
CN102625696B (en) 2009-06-10 2015-06-03 阿尔尼拉姆医药品有限公司 Improved Lipid Formulation
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
WO2021021567A1 (en) * 2019-07-26 2021-02-04 Merck Sharp & Dohme Corp. Methods and assemblies for preparing and dispensing lyospheres of pharmaceutical compositions
EP4021407A1 (en) 2019-08-30 2022-07-06 GlaxoSmithKline Biologicals S.A. Jet mixing lipid nanoparticle manufacturing process
CN111330003A (en) * 2020-03-23 2020-06-26 翁炳焕 Preparation method of novel coronary pneumonia antisense RNA multivalent vaccine
CN115996707A (en) * 2020-04-20 2023-04-21 德克萨斯大学系统董事会 Bioactive dry powder compositions and methods of making and using the same
CN112843019A (en) * 2021-01-27 2021-05-28 江苏普瑞康生物医药科技有限公司 Nucleic acid lipid nanoparticle composition, pharmaceutical preparation containing same, and preparation method and application thereof
US20240350410A1 (en) * 2021-08-16 2024-10-24 Glaxosmithkline Biologicals Sa Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
US20240408019A1 (en) * 2021-10-05 2024-12-12 Sanofi METHODS FOR FREEZING AND FREEZE-DRYING LIPID NANOPARTICLES (LNPs) AND LNPs OBTAINED WITH THE SAME
TW202415388A (en) * 2022-06-23 2024-04-16 美商輝瑞股份有限公司 Use of a spray freeze-drying process for the lyophilization of a mrna-encapsulating lipid nanoparticles formulation

Also Published As

Publication number Publication date
WO2025022327A1 (en) 2025-01-30

Similar Documents

Publication Publication Date Title
GB201916960D0 (en) Compositions
PL3683455T3 (en) Expansion connector
DK3924442T3 (en) Compositions
GB201903287D0 (en) Composition
FI3840581T3 (en) Diafiltration
IL290447A (en) Pharmaeutical composition comprising ensifentrine
CA210367S (en) Spatula
GB201901556D0 (en) Flexible interposer
PL3931452T3 (en) Expansion connector
IL289125A (en) Compositions
GB201908396D0 (en) Compositions
IL291119A (en) Etching composition
SG11202104198QA (en) Truss section connection region
GB2584778B (en) Trunnion Block Assembly
GB202311382D0 (en) Lyophilised compostion
CA210361S (en) Spatula
GB201915814D0 (en) Joint assembly
SG10201907786PA (en) Connection assembly
GB202312129D0 (en) Compostion
GB201903406D0 (en) Composition
GB201902054D0 (en) Composition
CA211502S (en) Pipe-to-fitting connection
GB202213465D0 (en) Nosohryak-uteivai133millioncirclexdotvaigaligaligaligaligmkgachachatchaman-aidohn15circlexdotgachachatchamanaidohn15circlexdot!ktkanjitsusohlinkyakuvaikanjits
GB202213466D0 (en) Nosohryak-uteivai133millioncirclexdotvaigaligaligaligaligmkgachachatchaman-aidohn15circlexdotgachachatchamanaidohn15circlexdot!ktkanjitsusohlinkyakuvaikanjits
GB202007454D0 (en) Spatula

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)